Topic Listing for GTC Biotherapeutics

Ability Negotiate Potential Marketing Partners Atryn Limited Existing Ability Negotiate Potential Marketing Partners Limited
Ability Negotiate Potential Marketing Partners Limited Existing Obligations Abstentions Broker Non-votes
Accounting Employee Equity Plans Accounting Stock-based Compensation
Accrued Liabilities Acquisition License Grant Appointment
Acquisition Licensing Development Supply Agreement Additional Information Deadline Stockholder Proposals Director Nominations
Additional Information Individual Case Report Additional Internal Pipeline Recombinant Blood Protein Programs
Additional Safety Information General Nature Address Change
Address Notice Address Notices Selling Securityholder
Adjustment Adjustments
Administration Advanced Cell Technologies Inc Act
Advantages Transgenic Production Technology Advantages Transgenic Technology
Agreement Agreement Not Compete
Agreement Sell Purchase Units Placement Agents Amended Restated Master Security Agreement
Amended Restated Security Agreement Amendment
Amendment 2002 Equity Incentive Plan Amendment Annual Adjustment Provision
Amendment Award Amendment Lease
Amendment Plan Amendment Shareholder Rights Agreement
Amendment Termination Amendments Articles Organization Bylaws Change
Amount Annex
Annual Meeting Stockholders Held 2006 Annual Option Awards
Annual Report Other Sec Filings Anti-takeover Provisions Charter By-laws Massachusetts Law Result Management
Antithrombin Deficient Patients Undergoing Surgery Appendix
Appraisal Rights Arbitration
Arrangements Genzyme Corporation Arrangements Related Parties
Assignability Assignment Form
Atiii Llc Re-acquisition Atryn
Atryn Commercial Clinical Progress Atryn Commercial Launch Activities Clinical Progress
Atryn Europe Middle East Canada Atryn Facetimes New Roman Size1
Atryn Recombinant Human Antithrombin Atryn Update
Attachment Articles Amendment Audit
Audit Committee Audit Committee Board Directors
Audit Committees Auditors
Authorized Shares Available Information
Awards Background
Background Information Balance Page Intentionally Left Blank
Base Salaries Base Salary
Basis Consolidation Basis Presentation
Bb-ind Means Biologic Investigational New Drug Application Filed Benchmark Data Compensation Consultants
Beneficial Ownership Registrable Securities Beneficial Ownership Reporting Compliance
Binding Board Directors
Board Directors Committee Matters Board Meetings Committees
Board Observer Director Board Representation
Board Representatives Bonuses Corporate Performance
Bonuses Individual Performance Borrowings
Boston 02199 Broker-dealer Status
Business Fail Due Intense Competition Industry Business Overview
Calendar Term Net Sales Product Equal Within Range Cambrex Bio Science Hopkinton
Cambrex Bio Science Inc Cannot Market Sell Transgenically Produced Products United States
Capital Raising Efforts Dilute Shareholder Interests Cash Equivalents
Cash Flows Financing Activities Cash Flows Investing Activities
Cash Flows Used Investing Activities Cash Flows Used Operating Activities
Cash Investment Position Cash Position
Cautionary Language Regarding Forward-looking Statements Cd137 Antibody
Cd20 Cd20 Follow-on Antibody
Cd20 Monoclonal Antibody Mab Certain Definitions
Certain Relationships Related Transactions Certain Relationships Transactions Related Parties
Certification Pursuant 302 Certification Pursuant 302 Sarbanes-oxley Act 2002
Change-in-control Changes Internal Controls
Changes Regulatory Requirements Check Appropriate Box
Chmp Opinion Marketing Authorization Application Atryn Clinical Trials Transgenically Produced Products Unsuccessful Delayed Prevent
Clinical Trials Transgenically Produced Products Unsuccessful Delayed Unable Closing Statement
Closings Delivery Units Funds Code 162 Provisions
Code Ethics Collaboration Governance
Collaboration Partners Fail Perform Satisfactorily Terminate Agreements Collaborations
Collateral Schedule 001 Collateral Schedule 002
Collateral Subsidiaries Commercialization Agreement
Commitments Contingencies Committee Discretion
Committees Common Stock Continue Volatile Public Trading Price
Common Stock Placements Common Stock Risk Delisting Nasdaq Capital Market
Common Stock Risk Delisting Nasdaq Global Market Common Stock Volatile Public Trading Price Low Volume
Commonwealth Massachusetts Communication Audit Committees
Communications Compared 2002
Compared 2003 Compared 2004
Compared 2005 Compared 2006
Compared 2007 Comparison Cumulative Total Return Among Gtc Biotherapeutics Inc
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Committee Report Executive
Compensation Deductibility Compensation Discussion Analysis
Compensation Other Fees Competing Products
Competition Compliance Certificate
Concentration Credit Risk Conclusion Regarding Effectiveness Disclosure Controls Procedures
Conference Call Information Confidential
Confidential Material Omitted Filed Separately Securities Exchange Asterisks Confidential Proprietary Information Agreement
Confidentiality Consent Amendment Capital Amended Restated Master Security Agreement
Consolidated Financial Statements Contact
Contact Additional Information Contact Information
Contact Persons Contractual Obligations
Controls Procedures Controversy
Conversion Subordinated Convertible Convertible
Convertible Debt Financing Coordinating Committee
Copy Filings Including Annual Report Form 10-k 2006 Copy Filings Including Annual Report Form 10-k 2007
Copy Filings Including Annual Report Form 10-k 2008 Covenants Representations Warranties
Cox Cox Chairman President Chief Executive Officer
Creation Direct Financial Obligation Creation Direct Financial Obligation Off-balance Sheet Arrangement
Creation Security Interest Credit Facilities
Credit Facility Critical Accounting Policies Estimates
Crossing Boulevard Framingham Massachusetts 01702 508 620-9700 Notice Current Resources Only Sufficient Fund Operations Short Term
Database Date
Deadline Shareholder Proposals Director Nominations Deadline Stockholder Proposals Director Nominations
Debt Financing Activities Default Remedies
Defense Trademarks Definitions
Delivery Funds Delivery Shares
Depend Collaboration Agreements Current Revenue Depend Collaboration Agreements Current Revenue Significant Funding
Depend Patents Proprietary Rights Fail Protect Business Description
Development Activities Development Costs
Development Plan Development Product Dic Sepsis Indication
Development Product Indication Dic Sepsis Indication Means Product Treatment Prevention Disseminated
Diligence Requirements Director Biographical Information
Director Compensation Director Fees
Directors Directors Executive Officers Registrant
Discretionary Voting Proxies Other Matters Dispute Resolution
Dividend Cash Awards Loans Documentation
Documents Incorporated Reference Dollars Except Per Share Amounts
Effective Date Term Plan Elan
Elan Agreement Electronic Delivery Future Shareholder Communications
Electronic Delivery Future Stockholder Communications Elements 2007 Executive Compensation Program
Eligibility Eligible Participants
Emea Provides Scientific Advice Study Atryn Dic Employees
Employment Agreements Enforcement Patent Rights
Entry Material Definitive Agreement Equipment Advances
Equity Awards Granted Equity Compensation Plan Information
Equity Financing Activities Equity Incentive Plan Awards
Equity Position Estimates
Europe European Scientific Advice Clinical Progress
Exact Name Registrant Specified Charter Example Calendar Term Ovations Net Sales Such Equal
Example Only Except Set Forth Below Undersigned Not Beneficial Registered
Execution Version Executive Compensation
Executive Officers Exercise Price Adjustments Certain Outstanding Warrants
Exhibits Expect Continue Incur Significant Operating Losses Next Several
Expect Incur Future Operating Losses Never Become Profitable Expenses Solicitation
Explanatory External Portfolio
External Program Portfolio External Programs
Face Public Concerns Genetic Engineering Animals Face Uncertainty Raising Additional Funds Operations
Fail Maintain Effective System Internal Controls Not Able Fail Obtain Necessary Regulatory Approval Market Sell Transgenically
Fair Value Federal Income Tax Consequences Relating Awards
Financial Position Financial Results
Financial Statements Financial Statements Exhibits
Financial Statements Statement Schedule Financial Statements Supplemental Schedules
Financing Activities Follow-on Biologics
Follow-on Biologics Biosimilars Following Summary Purchase Agreement Qualified Entirety Reference Read
Force Majeure Foreign National Awards
Form 10-k Form 10-q
Form Articles Amendment Form Incentive Stock Option Terms Conditions
Form Keepwell Agreement Form Legal Opinion Palmer Dodge Llp
Form Lock-up Agreement Form Nonstatutory Stock Option Non-employee Directors Terms Conditions
Form Nonstatutory Stock Option Terms Conditions Form Opinion Counsel
Former Name Address Changed Since Last Report Forward-looking Statement Gtc Biotherapeutics
Further Assurances Further Warranties
General General Information Voting
General Laws Chapter 1568 General Laws Chapter 156b
General Laws Chapter 156d 1006 950 Cmr 11334 General Provisions Applicable Awards
General Representations Warranties Genzyme Corporation
Genzyme Stock Buyback Genzymes Significant Ownership Interest Give Influence Over Matters
Geoffrey Cox Phd Chairman President Chief Executive Officer Geographical Information
Governing Law Government Regulation
Grant Options Grant Rights
Grants Plan-based Awards Grants Rights Licenses Jda
Green Green Senior Vice President Chief Financial Officer Treasurer
Gtc Biotherapeutics Gtc Biotherapeutics Announces Sale Common Stock
Gtc Biotherapeutics Anticipates Emea Opinion Atryn 2006 Gtc Biotherapeutics Expects Chmp Issue Negative Opinion Atryn
Gtc Biotherapeutics Inc Gtc Biotherapeutics Inc Offering Common Stock
Gtc Biotherapeutics Inc Proxy Solicited Behalf Board Directors Gtc Biotherapeutics Plans Respond Emea 2005
Gtc Biotherapeutics Provides Update European Regulatory Review Atryn Gtc Biotherapeutics Raise 167 Registered Direct Offering
Gtc Biotherapeutics Raise 175 Registered Direct Offering Gtc Biotherapeutics Receives Nasdaq Notice Non-compliance
Gtc Biotherapeutics Reports 2005 Financial Results Gtc Biotherapeutics Reports 2007 Financial Results
Gtc Biotherapeutics Reports 2008 Financial Results Gtc Biotherapeutics Reports 2009 Financial Results
Gtc Biotherapeutics Transfer Nasdaq Capital Market Gtc Biotherapuetics Inc
Guarantees Harry Meade Phd Senior Vice President Research Development
Held 2006 Held 2007
Held 2009 Hemophilia Programs
Herd Management Agreement Highlights
History Transaction Householding Annual Meeting Materials
Householding Special Meeting Materials Huntington Avenue Boston Massachusetts 02199-7613
Impact Existing Shareholders Impact Stockholders Approval Disapproval Proposal
Impact Tax Accounting Issues Implementing Proposed Amendment
Important Notice Regarding Availability Proxy Materials Shareholder Meeting Incentive Bonus
Incentive Stock Options Included Purchased Property
Income Taxes Inconsistencies
Incorporation Reference Increase Lfbs Control Position
Increase Number Shares Available Indemnification
Indemnification Provisions Independence
Independent Registered Public Accountants Fees Other Matters Index
Index Nasdaq Pharmaceutical Information
Information Concerning Solicitation Insurance
Intangible Assets Intellectual Property
Intellectual Property Rights Interest Rate Risk
Internal Control Over Financial Reporting Internal Revenue Code 162
Interpretation Application Introduction
Inventory Investor Questionnaire
Jcom Ltd John Green Senior Vice President Chief Financial Officer
Joint Development Collaboration Agreement Joint Development Commercialization Agreement
Landlord Legal Proceedings
Lending Arrangements Lfb Leo Pharma
Lfb Lfb Biotechnologies
Lfb Biotechnologies Sas Lfb Biotechnologies Sasu
Lfb Collaboration Agreement Lfb Collaboration Agreement Rhfviia
Lfb Stock Purchase Agreement Lfb Stockholder Largest Beneficial Ownership Common Stock Seek
License Grant Appointment License Grants
Licensing Supply Agreement Limit Individual Grants
Limited Manufacturing Capability Rely Party Contract Manufacturers Purify Limited Manufacturing Capability Required Rely Party Contract Manufacturers
Liposky Senior Vice President Operations Liquidity Capital Resources
List Exhibits Annexes List Merrimack Production Support Documentation
Litigation Loan Agreement
Loan Modification Agreement Lock-up Agreement
Long-lived Assets Long-term Debt
Lundbeck Inc Formerly Ovation Pharmaceuticals Maintenance Trademarks
Malaria Vaccine Malaria Vaccine Contract
Management Agreement Managements Report Internal Control Over Financial Reporting
Manufacture Product Manufacture Sale Products Expose Product Liability Claims Substantial
Manufacturing Service Agreement Market Registrants Common Equity Related Stockholder Matters Issuer
Marketable Securities Master Security Agreement
Meade Meade Senior Vice President Research Development
Medical Definitions Merrimack
Merrimack Pharmaceuticals Inc Messrs Liposky Woloshen
Middle East Minimum Vesting Requirements
Miscellaneous Monoclonal Antibodies Follow-on Biologics
Monoclonal Antibodies Mabs Immunoglobulin Fusion Proteins Monthly Line Listings
Name Name Person Filing Proxy Statement Other Registrant
Named Executive Agreements Nature Business
Need Additional Capital Fund Operations Including Research Development Negotiation Right Commercializing Atryn
Net Loss Per Common Share New Accounting Pronouncements
New Plan Benefits New Plan Benefits Table
New Zealand Goats Nominating Corporate Governance Committee
Non-binding Non-cash Investing Financing Transactions
Nonstatutory Stock Options Not Able Recover Catastrophic Event Affecting Animals Facilities
Not Form Exercise Warrant Notes Consolidated Financial Statements
Notes Regarding Forward-looking Statements Notice
Notice Annual Meeting Shareholders Held 2009 Notice Annual Meeting Stockholders Held 2007
Notice Exercise Notice Regarding Internet Availability Annual Meeting Materials
Notice Special Meeting Shareholders Held 2006 Notice Special Meeting Stockholders Held 2008
Notification Regulatory Authorities Now Therefore Consideration Mutual Covenants Undertakings Herein Contained
Now Therefore Consideration Premises Agreements Herein Contained Parties Number Votes Required
Obligations Issue Shares Common Stock Future Dilute Ownership Offsite Collateral
Option Exercises Stock Vested Option Exercises Stock Vested 2008
Option Purchase Additional Shares Series Preferred Stock Orders Shipments
Orphan Drug Designations Means Granted Fda Product Indication Other Benefits
Other Events Other Financial Results
Other Internal Pipeline Programs Other Partnering Update
Other Programs Other Recombinant Plasma Proteins
Ovation Pharmaceuticals Ovation Pharmaceuticals Inc
Overview Ownership
Part Part Other Information
Participation Important Please Vote Today Participation Negotiation Rights Respect Future Security Offerings
Participation Negotiation Rights Respect Future Security Offerings Registration Participation Rights
Parties Elaborate Further Leo Separately Forwarded Proposal Standard Partnering Strategy
Patent Prosecution Patents Proprietary Rights
Payment Payments Termination Change-in-control
Performance Bonus Program Pharmacovigilance Procedures Agreement
Pharmathene Inc Pharming Group
Philosophy Objectives Compensation Program Plan
Plan Distribution Please Fax Copy Completed Executed Notice Questionnaire Return
Please Indicate Compliance Status Circling Yes Complies Column Please Vote Shares Now Counted Without Delay Voting
Pledged Shares Policy Related Person Transactions
Portfolio External Programs Possible Using Enclosed Reply Envelope
Post Marketing Sadr Reports Post-closing Requirements
Potential Change Control Potential Effect Proposed Amendment Holders Common Stock
Pre-approval Policy Preceding Articles Considered Permanent Changed Only Filing Appropriate
Preferred Stock Placements Pregnancy Cases
Pricing Information Principal Accountant Fees Services
Prior Authorization Effect Reverse Stock Split Pro Rata
Procedure Ordering Forecasting Products Clinical Trials Commercial Sale Procedures Stockholders Nominate Directors
Product Portfolios Partnering Product Supply
Products Promissory
Property Plant Equipment Proposal
Proposal Approval Amendment Restatement 2002 Plan Proposal Considered Annual Meeting
Proposal Considered Special Meeting Proposal Election Directors
Proposal Ratification Independent Registered Public Accounting Firm Proposals Considered Annual Meeting
Proposals Considered Special Meeting Proprietary Product Programs
Protections Rights Bankruptcy Other Failures Proxy Annual Meeting Shareholders 2009
Proxy Annual Meeting Stockholders 2007 Proxy Special Meeting Stockholders 2008
Proxy Statement Proxy Statement Pursuant Securities Exchange Act 1934
Proxy Statement Pursuant Securities Exchange Act 1934 Amendment Proxy Statement Special Meeting Stockholders Held 2008
Publication Purchase Agreement
Purpose Purpose Amendment
Purpose Effect Amendment Pursuant Subsection Above Less Net Sales
Qualified Managerial Scientific Personnel Scarce Industry Quality Agreement
Quantitative Qualitative Disclosures Market Risk Quorum
Reason Request Shareholder Approval Reason Request Stockholder Approval
Reasons Amendment Reasons Amendment Restatement
Recitals Reclassifications
Recombinant Alpha-1 Antitrypsin Rhaat Recombinant Factor Rhfix
Recombinant Factor Viia Rhfviia Recombinant Human Albumin Rha
Recombinant Human Antithrombin Atryn Recombinant Plasma Protein Products
Recommendation Board Directors Records Audit
Recovery Catastrophic Event Not Adequate Redeemable Convertible Preferred Stock
Regarding Forward-looking Statements Regarding Reverse Stock Split
Registered Direct Offering Registrants Telephone Number Including Area Code
Registration Rights Regulation Disclosure
Regulatory Authority Means Federal State Territory Responsibility Approving Regulatory Authority Requests Additional Information
Regulatory Requirements Relationship Other Proposals
Relationships Remainder Page Intentionally Blank
Remainder Page Intentionally Left Blank Remainder Page Left Blank Intentionally Ignature Follows
Repayment Genzyme Report Audit Committee
Report Independent Registered Public Accounting Firm Reports
Reports Literature Representations Warranties
Representations Warranties Covenants Debtor Repricing Options
Required Consents Approvals Required Stockholder Approvals
Research Development Agreement Research Development Costs
Restricted Stock Restricted Stock Units
Results Operations Results Operations Financial Condition
Results Quarterly Operations Retention Incentive Plan
Retention Plan Retention Plan Awards
Revenue Recognition Revenue Recognition Contract Accounting
Reverse Stock Split Revoke Proxy
Rha Rhaat
Right Employment Rights Obligations Termination
Rights Stockholder Risks Related Business
Risks Related Common Stock Role Executive Officers Compensation Decisions
Royalty Payment Gtc Such Calendar Royalty Payments
Sadr Data Exchange Safety Reports
Sale Convertible Warrant Lfb Biotechnologies Sasu Sarbanes-oxley Act 2002
Schedule 14a Proxy Statement Pursuant Securities Exchange Act Schedule 2008 Retention Plan Awards Named Executive Officers
Schedule Retention Plan Awards Named Executive Officers Scope Agreement
Scope Collaboration Joint Obligations Diligence Secretary Commonwealth
Sections Securities Exchange Act 1934 Securities Authorized Issuance Equity Compensation Plans
Securities Purchase Agreement Securities Registered Pursuant Act
Security Agreement Security Ownership Certain Beneficial Owners Management Related Stockholder
Selling Securityholder Notice Questionnaire Separately Securities Exchange
Series Preferred Stock Services
Services Agreement Share-based Compensation
Share-based Payment Shared Liability Claims
Shareholder Communications Shareholder Rights Plan
Signaling Signature
Signature Block Corporation Partnership Trust Other Entity Signature Block Natural Person
Signature Holder Signature Page Acquisition Licensing Development Supply Agreement
Signature Page Amendment Mortgage Signature Page Collateral Schedule 002
Signature Page Consent Amendment Amended Restated Master Security Signature Page Follows
Signature Page Patent License Security Agreement Signature Page Trademark License Security Agreement
Signature Pages Follow Signatures
Signatures Following Page Significant Accounting Policies
Significant Agreements Leo Pharma Source Material Collection Processing
Special Protections Ssadr Reports Clinical Trials
Standards Care Compliance Law Statement Facts
Stock Appreciation Rights Stock Available Awards
Stock Awards Stock Equivalents
Stock Options Stock Performance Graph
Stock Purchase Agreement Stock Warrants
Stockholder Communications Stockholders Deficit
Stockholders Equity Strategic Elements Growth
Sublease Agreement Sublicenses Gtc
Sublicenses Lfb-us Submission Matters Vote Security Holders
Subscription Agreement Subsequent Events
Subsidiaries Gtc Biotherapeutics Inc Successful Commercialization Products Depend Obtaining Coverage Reimbursement Third-party
Sum Royalty Payments Gtc Such Calendar Summary 2002 Equity Plan
Summary 2002 Plan Summary Compensation Table
Supply Agreement Support New Indications
Table Table Contents
Taurus Hsa Llc Taxes
Technology Transfer Agreement Tenant
Term Term Loan
Term Option Term Termination
Termination Rights Termination Service
Terms Conditions Terms Conditions Purchase Units
Therefore Whether Not Plan Attend Meeting Please Complete Title Each Class
Trademark Status Report Trademarks
Transferability Transgenic Production Technology
Transgenic Technology Relatively Early Stage Transgenically Produced Products Never Become Commercially Successful
Transgenically Produced Products Obtain Regulatory Approval Subject Continuing Transgenically Produced Products Other Atryn Early Stage Development
Transgenically Produced Products Subject Technology Risks Restrict Prevent Treasurer
Treasury Stock Tufts University School Veterinary Medicine
Unable Attract Retain Qualified Managerial Scientific Personnel Adversely Unable Raise Additional Capital Needed Develop Commercialize Product
United States Unregistered Sales Equity Securities
Unrestricted Stock Validation Costs
Valuation Intangible Long Lived Assets Valuation Intangible Long-lived Assets
Vote Vote Internet Wwwproxyvotecom
Vote Mail Vote Phone 1-800-690-6903
Vote Required Vote Shares Person
Vote Shares Proxy Vote Shares Proxy Card
Vote Shares Telephone Internet Votes
Votes Required Voting Results
Voting Results Special Meeting Shareholders Warrant
Warrant Purchase Agreement Warrant Purchase Common Stock
Warrants William Francis Galvin
Withholding Taxes 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki